Trial reportPloS one2012
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype.
Trial report in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 373 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
A Predictive "Molecular Biology Signature" for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease
Who cites it
373 citing papers in PubMed, 3 syntheses or guidelines pooled it, 837 citations in OpenAlex.
- Prognostic Value of Multifrequency Bioelectrical Impedance Analysis in Chronic Obstructive Pulmonary Disease: Systematic Review.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Epicardial adipose tissue in patients with chronic obstructive pulmonary disease: systematic review with meta‑analysis and trial sequential analysis.BMC pulmonary medicine · 2023Pooled it
- Fibrinogen is a promising biomarker for chronic obstructive pulmonary disease: evidence from a meta-analysis.Bioscience reports · 2020Pooled it
- Research on the effectiveness and safety of bronchial thermoplasty in patients with chronic obstructive pulmonary disease.European journal of medical research · 2023Trial
- Trial
- Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD.Respiratory research · 2019Trial
- Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial.BMJ open respiratory research · 2019Trial
- Multidimensional Inflammatory Biomarker Profiling in COPD: A Latent Inflammatory Construct Associated with Disease Severity and Exacerbation Burden.Diagnostics (Basel, Switzerland) · 2026Article
- Oxidative Stress and Inflammatory Cytokines as Drivers of Cardiac Remodeling in COPD Patients.Antioxidants (Basel, Switzerland) · 2026Article
- Trajectory of preserved ratio impaired spirometry (PRISm): patterns, predictors, and potential interventions.Clinical and experimental medicine · 2026Review
- Peripheral Blood Neutrophil-Monocyte-to-Lymphocyte Ratio and Long-Term All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Primary Care Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Blood viscosity is associated with smoking status rather than the presence of chronic obstructive pulmonary disease: findings from the Korea COPD Subgroup Study (KOCOSS).Respiratory research · 2026Article
- COPD is associated with poorer survival in patients with advanced non-small cell lung cancer treated with first-line ICI plus chemotherapy.BMC pulmonary medicine · 2026Article
- Effects of Fine Particulate Matter on Systemic Inflammatory Biomarkers in Elderly Patients with Chronic Obstructive Pulmonary Disease Versus the Healthy Elderly: A Pilot Study.International journal of molecular sciences · 2026Article
- Pathogenesis and Phenotypes of Pulmonary Vascular Disease in COPD: A Consensus Statement From the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - PH Group 3 Workstream.Pulmonary circulation · 2026Article
- Chronic obstructive pulmonary disease as a systemic risk factor for cancer: a nationwide cohort study in Korea.BMJ open respiratory research · 2026Article
- Immune system benefits of pulmonary rehabilitation in chronic obstructive pulmonary disease.Experimental physiology · 2026Review
- The systemic impact of acute exacerbations of COPD requiring hospitalisation: a narrative review.ERJ open research · 2026Review
- Global trends and research hotspots in pulmonary rehabilitation for chronic obstructive pulmonary disease: a bibliometric analysis (2000-2024).Journal of thoracic disease · 2026Article
- Comparison of chest CT-derived muscle mass and body mass index in assessing disease severity and outcomes in non-cystic fibrosis bronchiectasis.BMC pulmonary medicine · 2026Article
313 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 13 institutions in 7 countries.
Funding
Abstract
backgroundBecause chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of specific clinical phenotypes is key to developing more effective therapies. To explore if the persistence of systemic inflammation is associated with poor clinical outcomes in COPD we assessed patients recruited to the well-characterized ECLIPSE cohort (NCT00292552). METHODS AND
findingsSix inflammatory biomarkers in peripheral blood (white blood cells (WBC) count and CRP, IL-6, IL-8, fibrinogen and TNF-α levels) were quantified in 1,755 COPD patients, 297 smokers with normal spirometry and 202 non-smoker controls that were followed-up for three years. We found that, at baseline, 30% of COPD patients did not show evidence of systemic inflammation whereas 16% had persistent systemic inflammation. Even though pulmonary abnormalities were similar in these two groups, persistently inflamed patients during follow-up had significantly increased all-cause mortality (13% vs. 2%, p<0.001) and exacerbation frequency (1.5 (1.5) vs. 0.9 (1.1) per year, p<0.001) compared to non-inflamed ones. As a descriptive study our results show associations but do not prove causality. Besides this, the inflammatory response is complex and we studied only a limited panel of biomarkers, albeit they are those investigated by the majority of previous studies and are often and easily measured in clinical practice.
conclusionsOverall, these results identify a novel systemic inflammatory COPD phenotype that may be the target of specific research and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.